0001493152-21-014435.txt : 20210615 0001493152-21-014435.hdr.sgml : 20210615 20210615171433 ACCESSION NUMBER: 0001493152-21-014435 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20210615 DATE AS OF CHANGE: 20210615 EFFECTIVENESS DATE: 20210615 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BriaCell Therapeutics Corp. CENTRAL INDEX KEY: 0001610820 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: A1 FISCAL YEAR END: 0731 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-403035 FILM NUMBER: 211019556 BUSINESS ADDRESS: STREET 1: 3RD FLOOR, BELLEVUE CENTRE, 235-15TH STR CITY: WEST VANCOUVER STATE: A1 ZIP: V7T 2X1 BUSINESS PHONE: (604) 921-1810 MAIL ADDRESS: STREET 1: 3RD FLOOR, BELLEVUE CENTRE, 235-15TH STR CITY: WEST VANCOUVER STATE: A1 ZIP: V7T 2X1 FORMER COMPANY: FORMER CONFORMED NAME: Ansell Capital Corp. DATE OF NAME CHANGE: 20140613 D 1 primary_doc.xml X0708 D LIVE 0001610820 BriaCell Therapeutics Corp. SUITE 300-235 15TH STREET WEST VANCOUVER A1 BRITISH COLUMBIA, CANADA V7T2X1 (604) 921-1810 BRITISH COLUMBIA, CANADA None Ansell Capital Corp. Corporation true William Williams Suite 300-235 15th Street West Vancouver A1 BRITISH COLUMBIA, CANADA V7T2X1 Executive Officer Director Gadi Levin Suite 300-235 15th Street West Vancouver A1 BRITISH COLUMBIA, CANADA V7T2X1 Executive Officer Rebecca Taub Suite 300-235 15th Street West Vancouver A1 BRITISH COLUMBIA, CANADA V7T2X1 Director Vaughn Embro-Pantalony Suite 300-235 15th Street West Vancouver A1 BRITISH COLUMBIA, CANADA V7T2X1 Director Jamieson Bondarenko Suite 300-235 15th Street West Vancouver A1 BRITISH COLUMBIA, CANADA V7T2X1 Executive Officer Director Martin Schmieg Suite 300-235 15th Street West Vancouver A1 BRITISH COLUMBIA, CANADA V7T2X1 Director Pharmaceuticals Decline to Disclose 06b false 2021-06-03 false true true true false 0 ThinkEquity, a division of Fordham Financial Management, Inc. 20996 None None 17 BATTERY PLACE, SOUTH NEW YORK NY NEW YORK 10004 CA CALIFORNIA NV NEVADA NJ NEW JERSEY NY NEW YORK false 27195924 27195924 0 Offering consists of 4,370,343 common shares at a purchase price of USD 5.26; 800,000 pre-funded warrants at a purchase price of USD 5.25 with an exercise price of USD 0.01 per share and 5,170,343 warrants with an exercise price of USD 6.19 per share false 12 2175680 0 The above amount reflects a cash fee equal to 8% of gross proceeds, including exercise price of the pre-funded warrants. The Placement Agent also received a number of warrants equal to 5% of the Units sold in this offering. 0 true false BriaCell Therapeutics Corp. /s/ William V. Williams William V. Williams Chief Executive Officer 2021-06-15